Back to Clinical Trials
Phase 1Recruiting

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Sponsored by Nuvectis Pharma, Inc.

About this study

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)

Where this study is enrolling

Who can participate

Inclusion criteria

  • ✓1. Provide written informed consent.
  • ✓2. 18 years old or older.
  • ✓3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • ✓4. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
  • ✓5. Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.

Exclusion criteria

  • ✕1. Subject's cancer has a known oncogenic driver alteration other than EGFR.
  • ✕2. Known EGFR mutations that cause resistance to osimertinib
  • ✕3. Known human epidermal growth factor receptor 2 (HER2) overexpression
  • ✕4. Any contraindications to treatment with osimertinib

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.